✦ LIBER ✦

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

✍ Scribed by Gertz, M A; Lacy, M Q; Dispenzieri, A; Ansell, S M; Elliott, M A; Gastineau, D A; Inwards, D J; Micallef, I N M; Porrata, L F; Tefferi, A

Book ID: 110014349
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 136 KB
Volume: 34
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1704691

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Renal Response After High-Dose Melphalan

Renal Response After High-Dose Melphalan and Stem Cell Transplantation Is a Favorable Marker in Patients With Primary Systemic Amyloidosis

✍ Nelson Leung; Angela Dispenzieri; Fernando C. Fervenza; Martha Q. Lacy; Rafael V 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 215 KB

Febrile Reactions Occurring With Second

Febrile Reactions Occurring With Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis: A “Melphalan Recall” Reaction

✍ M.A. Rosenzweig; D.C. Seldin; D. Remick; M. Skinner; K. Quillen; B. Oran; K.T. F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Risk-factors of melphalan/fludarabine do

Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ N. Kroger; J.A. Perez-Simon; H. Myint; H. Klingemann; A. Shimoni; A. Nagler; R. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Feasibility of a dose-adjusted fludarabi

Feasibility of a dose-adjusted fludarabine–melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma

✍ Andrea Tendas; Luca Cupelli; Teresa Dentamaro; Laura Scaramucci; Roberto Palumbo 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 57 KB

High-dose melphalan and stem cell transp

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

✍ Tsai, S. B.; Seldin, D. C.; Quillen, K.; Berk, J. L.; Ruberg, F. L.; Meier-Ewert 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 161 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame